Targeting Cannabinoid Receptors in HER2 positive tumours.

靶向 HER2 阳性肿瘤中的大麻素受体。

• 批准号: 2892094
• 金额: --
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2892094
• 关键词: Targeting; Cannabinoid; Receptors; HER2; positive

HER2+ breast cancer is characterised by the overexpression of the HER2 receptor tyrosine kinase. This aggressive subtype accounts for around 20% of breast cancer cases. However, despite success with targeted therapies resistance is still a concern. This is especially the case for patients with metastatic disease. Cannabinoid 2 receptor (CB2R) expression has been shown to be induced by HER2 expression and presents an appealing novel druggable target. This work aims to characterise the pharmacological properties and phenotypic impacts of HER2- and CB2-targeted therapies. Using 2D and 3D in vitro models with inducible CB2R expression, the metabolic and invasive characteristics of tumours after CB2R modulation will be dissected further. This is with an endpoint to test proprietary synthetic cannabinoids that aim to modulate the pro-tumorigenic actions of CB2Rs.

HER2+乳腺癌的特征是HER2受体酪氨酸激酶的过表达。这种积极的亚型约占乳腺癌病例的20％。但是，尽管有针对性的疗法抗性成功仍然是一个问题。对于转移性疾病患者而言，情况尤其如此。大麻素2受体（CB2R）的表达已被证明是由HER2表达诱导的，并提出了一个有吸引力的新型可药物靶标。这项工作旨在表征HER2和CB2靶向疗法的药理特性和表型影响。使用具有诱导CB2R表达的2D和3D体外模型，将进一步阐述CB2R调节后肿瘤的代谢和侵入性特征。这是测试专有合成大麻素的终点，旨在调节CB2RS的亲瘤作用。